IDEXX Laboratories, Inc. (NASDAQ:IDXX) Stake Raised by V Square Quantitative Management LLC

V Square Quantitative Management LLC boosted its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 6.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,076 shares of the company’s stock after acquiring an additional 121 shares during the quarter. V Square Quantitative Management LLC’s holdings in IDEXX Laboratories were worth $858,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Creative Planning lifted its stake in IDEXX Laboratories by 2.6% during the third quarter. Creative Planning now owns 24,436 shares of the company’s stock valued at $12,346,000 after buying an additional 614 shares in the last quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd lifted its position in shares of IDEXX Laboratories by 19.0% in the third quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 3,306 shares of the company’s stock worth $1,670,000 after purchasing an additional 529 shares in the last quarter. Bleakley Financial Group LLC increased its holdings in IDEXX Laboratories by 1.4% in the third quarter. Bleakley Financial Group LLC now owns 2,861 shares of the company’s stock worth $1,445,000 after buying an additional 39 shares during the last quarter. Marshall Financial Group LLC increased its holdings in IDEXX Laboratories by 1.6% in the third quarter. Marshall Financial Group LLC now owns 1,884 shares of the company’s stock worth $952,000 after buying an additional 30 shares during the last quarter. Finally, Cardinal Capital Management increased its holdings in IDEXX Laboratories by 0.7% in the third quarter. Cardinal Capital Management now owns 13,919 shares of the company’s stock worth $7,032,000 after buying an additional 93 shares during the last quarter. 87.84% of the stock is currently owned by institutional investors.

IDEXX Laboratories Stock Performance

Shares of NASDAQ:IDXX opened at $444.53 on Friday. IDEXX Laboratories, Inc. has a twelve month low of $398.50 and a twelve month high of $583.39. The firm has a market cap of $36.40 billion, a PE ratio of 41.66, a price-to-earnings-growth ratio of 3.47 and a beta of 1.37. The company has a debt-to-equity ratio of 0.28, a quick ratio of 1.03 and a current ratio of 1.31. The business has a fifty day moving average of $430.77 and a 200-day moving average of $453.31.

Wall Street Analysts Forecast Growth

Several brokerages have commented on IDXX. Piper Sandler increased their price target on IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a report on Monday, February 10th. Bank of America raised their target price on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 4th. Leerink Partnrs raised IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. Barclays lifted their price objective on IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a report on Tuesday, February 4th. Finally, StockNews.com cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, February 5th. Four analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $533.75.

Insider Activity

In related news, EVP George Fennell sold 9,986 shares of IDEXX Laboratories stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the sale, the executive vice president now directly owns 8,176 shares in the company, valued at $3,781,645.28. This trade represents a 54.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Sophie V. Vandebroek sold 344 shares of IDEXX Laboratories stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total value of $144,631.36. Following the completion of the sale, the director now owns 905 shares of the company’s stock, valued at approximately $380,498.20. The trade was a 27.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 13,330 shares of company stock worth $6,161,276. 2.11% of the stock is owned by corporate insiders.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.